CBD
The kerfuffle over a second gambling palace for Sydney may be distracting others, but it has not stopped pokies king Bruce Mathieson extending his winning streak at that other big casino, the stock exchange.
Mathieson's latest punt is a stake in biotech outfit iSonea, where his company Investment Holdings has snapped up 18.59 per cent.
ISonea, which is developing a mobile phone app for monitoring asthma, has been for a bit of a run since April, with its share price soaring from under 10¢ to close at 49¢ on Thursday.
By CBD's calculations, that puts Mathieson $7.42 million ahead on his stake, which was disclosed to the ASX on Monday. Part of that profit comes courtesy of a capital raising last week in which he spent $7 million to buy 20 million shares at 35¢ each. But Mathieson's real jackpot comes from his decision to outlay just $525,000 and snap up 10.5 million shares at just 5¢ each in a November rights issue.
ISonea's bull run has onlookers marvelling. "It's the most remarkable increase in market cap I have seen in a long time," Biotech Daily editor David Langsam told CBD.
Wirth-while?
Judging from the front page of a casino industry publication on Monday, Australia's best-known faceless man, Australian Workers Union boss Paul Howes, is back from his holidays.
Howes is stepping out with Qantas spin doctor Olivia Wirth, and one of the benefits of being involved with someone at the flying kangaroo is a whopping 90 per cent off the price of airfares.
So did Howes get a Wirth-while discount on flights to his as-yet-undisclosed holiday destination? Alas, no one was telling on Monday. Howes and Wirth did not return calls to their mobile phones, and a Qantas spokeswoman gave a comment that was about as informative as one of those garbled airport announcements: "Common to most airlines, all Qantas staff can access discounted travel as part of their employment, which can be extended to a limited number of beneficiaries."
Not so stellar
Less than stellar times at Stellar Securities, the Perth stockbroker whose landlord on Monday locked staff out of its office. The man to whom everyone, including CBD, wants to talk is Stellar's managing director, Nathan Barbarich.
Sadly, Barbarich was not answering the phone on Monday, and, ensconced in an east coast office, CBD was too far away from Western Australia simply to drop around to his home and see if anyone was there.
Property records show Barbarich lives a couple of doors down from the beach in Perth suburb Cottesloe, in a home he bought for $1.32 million in 2006.
In addition to the usual mortgage (to NAB), the property is also encumbered by two recent caveats, slapped on it by people who claim Barbarich owes them money.
Sharic Superannuation, controlled by Richard and Sharman Farris of Karrinyup, placed a caveat in April, citing a loan agreement.
Car and equipment finance outfit Morris Finance came out of the woodwork in May, lodging another caveat on the property on the basis of a guarantee allegedly signed by Barbarich.
If Barbarich is not at home, those seeking him might be best off looking out to sea - CBD hears he owns a cigarette boat, a type of high-speed powerboat. Or he might be out on the highway, looking for adventure on his hog - his LinkedIn page boasts that he is a life member of the Harley-Davidson Owners Group.
If Twitter is any guide, one place he would prefer not to be found is in the skies.
Virgin Australia is the "worst airline ever!", one Nathan Barbarich twice tweeted in February.
Qantas copped it in April last year, with its business class slammed for the "worst service ever!".
Got a tip?
bbutler@fairfaxmedia.com.au
Frequently Asked Questions about this Article…
Bruce Mathieson, described in the article as the pokies king, has attracted attention after his company Investment Holdings disclosed an 18.59% stake in biotech developer iSonea to the ASX. The stake became notable because iSonea’s share price has surged recently, and CBD calculated Mathieson was about $7.42 million ahead on his position after buying shares at different capital-raising prices.
iSonea is developing a mobile phone app for monitoring asthma. According to the article, its share price ran from under $0.10 to close at $0.49 on Thursday, prompting industry comment — Biotech Daily editor David Langsam called it "the most remarkable increase in market cap" he had seen in a long time.
The article reports Mathieson bought 20 million iSonea shares in a recent capital raising at $0.35 each (costing about $7 million) and had earlier spent $525,000 to acquire 10.5 million shares at $0.05 each in a November rights issue. Those different entry prices contributed to the sizable paper gain noted by CBD.
Yes — the article says Mathieson’s stake was disclosed to the ASX on Monday. Such ASX disclosures notify the market about significant changes in major shareholdings, which can be relevant information for everyday investors tracking ownership and potential influence in a company.
The article reports that Stellar Securities, a Perth stockbroker, experienced a disruptive event when its landlord locked staff out of the office. The firm’s managing director, Nathan Barbarich, was not answering calls when CBD tried to reach him, making the situation notable for clients and observers.
Property records cited in the article show two caveats were lodged on Nathan Barbarich’s home: Sharic Superannuation (controlled by Richard and Sharman Farris) placed a caveat in April citing a loan agreement, and Morris Finance lodged another caveat in May citing a guarantee allegedly signed by Barbarich. The article presents these caveats as claims that he owes money to those parties.
Yes. The article notes Australian Workers Union boss Paul Howes has been seen with Qantas spin doctor Olivia Wirth and remarks that one benefit of a Qantas connection can be a very large airfare discount (the piece mentions a ‘whopping 90 per cent off’). A Qantas spokeswoman told the article that, as is common with many airlines, Qantas staff can access discounted travel that can be extended to a limited number of beneficiaries.
The article highlights that industry observers have been surprised by iSonea’s rapid rise — Biotech Daily’s editor called it a remarkable increase in market cap. For everyday investors, the article’s coverage indicates the stock has drawn significant market attention, which is a factual signal that the company’s share price movement is noteworthy.
Call 1300 880 160
Start a chat
Schedule a call
